Navigation Links
Pharmaceuticals sold in Sweden cause serious environmental harm in India
Date:2/5/2009

Many of the substances in our most common medicines are manufactured in India and China. Some of these factories release large quantities of antibiotics and other pharmaceutical substances to the environment. There is an obvious risk of these releases leading to resistant bacteria.

Research from the Sahlgrenska Academy at University of Gothenburg, Sweden, shows that Sweden is a major consumer of pharmaceutical substances from factories that fail to adequately treat their wastewater. As it is difficult to find out where the pharmaceutical substances are manufactured and how much is released, it is impossible at present for consumers to avoid contributing to this environmental harm.

These findings are presented in the medical journal Regulatory Toxicology and Pharmacology and are highlighted today in a news article in Nature. Last week the research of the Swedish group became headline news in New York Times, Washington Post and Times of India.

"We used to think that pharmaceuticals that ended up in the environment mostly came from the use of the medicines and that the substances were dispersed through wastewater. We now know that certain factories that manufacture substances release very large quantities of active substances," says associate professor Joakim Larsson of the Sahlgrenska Academy in Gothenburg,Sweden, one of the research scientists behind the studies.

The water from the pharmaceutical industries is highly toxic

Joakim Larsson has visited the industrial zone near Hyderabad, India, an important centre for the manufacturing of pharmaceutical substances. Here his research team has taken samples of the water discharged from a treatment plant that treats wastewater from around 90 pharmaceutical factories before it is released.

"We have previously shown that the "treated" water contained exceptionally high levels of various pharmaceutical substances, including several broad-spectrum antibiotics. We estimated that the treatment plant released 45 kilograms of the antibiotic ciprofloxacin in one day, which is equivalent to five times the daily consumption of Sweden," says Larsson.

Such high levels of antibiotics in the water are a cause for alarm as there is an increased risk of spawning resistant bacteria, an issue of global concern. This can lead to those antibiotics that are invaluable today becoming ineffective sooner and not killing the bacteria of tomorrow. In addition, the environment is affected locally by the pollution; In another study by Larsson's team, published this week in Environmental Toxicology and Chemistry, they show that effluent diluted as much as 500 times strongly inhibit the growth of frog tadpoles.

The substances manufactured in Hyderabad are sold in Sweden

Where the active substance in a pharmaceutical product is manufactured is not public information, but the Swedish Medical Products Agency can grant exemptions for research purposes. The researchers analyzed data from the Medical Products Agency for all 242 products on the Swedish market that contained any of nine specific substances*. They found that 123 products contained substances from India and for 74 of the products, 31 per cent, the active substance was manufactured by one of the factories that send their wastewater to the treatment plant outside Hyderabad that was studied.

"The analysis shows quite clearly that a large number of medicinal products on the Swedish market is made by manufacturers that send their effluent to a treatment plant that does not treat their water satisfactorily," says Larsson.

We bear part of the responsibility

" Sweden, which is reputed to have some of the strictest environmental legislation in the world, like other western countries therefore bears a shared responsibility for the environmental problems the medicines we consume cause in India, for example," says Larsson.

But it is impossible for the individual consumer to know today whether a substance in a medicine he or she needs to take may have caused environmental problems in manufacturing.

"It is therefore important that the production chain is made transparent. If consumers are given an opportunity to choose pharmaceutical products they know to be produced in an environmentally friendly way, this could encourage manufacturers to become more environmentally friendly," says Larsson.


'/>"/>

Contact: Joakim Larsson
joakim.larsson@fysiologi.gu.se
46-070-962-1068
University of Gothenburg
Source:Eurekalert

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
2. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
3. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
5. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. ISTA Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
7. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
8. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
10. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
11. Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
(Date:4/26/2017)... ... 2017 , ... Infertility may be a result of an ... many women become pregnant upon treating their diagnosis. , To properly ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
Breaking Medicine Technology: